MEDP

Medpace Holdings, Inc.

HALAL

Score: 85/100

stock

Is MEDP Halal?

Leading full-service clinical contract-research organization (CRO) — permissible clinical-research-and-development-services business with a strong, low-leverage financial-screen profile.

What You Should Know

Medpace Holdings, Inc. is one of the largest publicly-traded full-service clinical contract-research organizations (CROs) in the world, providing scientifically-driven, clinical-development-services to the biotechnology, pharmaceutical, and medical-device industries. Medpace operates a single integrated clinical-research-services platform spanning Phase I through Phase IV clinical-trial management, regulatory-affairs and regulatory-submission services, clinical-monitoring and clinical-operations services, central-laboratory and bioanalytical-laboratory services, medical-writing and biostatistics-and-data-management services, pharmacovigilance and drug-safety services, and core-laboratory imaging services across major therapeutic areas including oncology, metabolic disease, cardiology, central-nervous-system, anti-infective, and rare-disease research. Medpace is differentiated by its concentration on small-and-mid-sized biotechnology-and-pharmaceutical sponsors and its full-service, therapeutically-aligned operating model. Clinical-research-services, clinical-trial management, regulatory-affairs services, central-laboratory services, and biostatistics-and-data-management services are unambiguously permissible at the activity level under standard Sharia methodology — these are general-purpose healthcare-research-and-development services. The financial screen passes comfortably: Medpace operates a net-cash or very-low-leverage balance sheet with strong free-cash-flow conversion typical of an asset-light services business; the debt-to-market-cap ratio sits well below the 33% Sharia threshold. Most major Sharia advisory boards classify Medpace as permissible with purification of small interest-income components.

⚠️ Concerns

•Minor interest income on cash and short-term investment balances — purification of a small portion of income may be advisable; Medpace operates a net-cash or very-low-leverage balance sheet, so interest income is the principal screening consideration rather than debt
•Customer base is concentrated in small-and-mid-sized biotechnology-and-pharmaceutical sponsors — biotech-funding-cycle volatility can affect new-business bookings; this is a business-cycle consideration rather than a Sharia screen concern
•Some downstream pharmaceutical-and-biotech clients develop products with impermissible end-uses (alcohol-containing formulations or porcine-derived excipients) — under standard Sharia screening methodology, the relevant industry classification is general-purpose clinical-research-services rather than the look-through end-use product mix
•Medpace conducts clinical research across a broad therapeutic-area mix including oncology, metabolic, cardiology, and rare-disease research — these are general-purpose healthcare-research activities and are permissible at the activity level
•Debt-to-market-cap ratio should be re-verified against the 33% Sharia threshold at the time of investment given the company's history of share-repurchase activity that can modestly increase net leverage
•Medpace does not pay a dividend and returns capital primarily through share repurchases — this is a capital-allocation consideration rather than a Sharia screen concern